There are many who are honest with their choices who have not always maximized opportunities.
That imperfection is not a character flaw as some may assert, but comes with the territory investing in the Market.
The list of dissimilar performance with cut and paste accolades is tremendously long particularly in biotech.
Specific to Anavex is the continuing ambivalent commentary about BIIB for both the MOA and Cost....both of which (as with A2-73) have yet to be proven. I came to Anavex because of the novel approach and will continue to participate in my own style as THAT is pursued. Good Luck to all who do that responsibly. BTW...
6X or 10X are still significant "hits" and the difference will be the future deployment of realized gains.
Market Data 
Markets 
AI
